智通财经APP讯，瑞普生物(300119.SZ)发布公告，近日，公司收到了农业农村部颁发的猪流行性腹泻病毒mRNA疫苗(RPS1903)临床试验批件(批件号：2025061)。
此次获得的临床批件，是国内首个经济动物用mRNA疫苗临床批件。mRNA疫苗通过精准编码猪流行性腹泻病毒的关键抗原序列，进入机体后直接引导细胞合成抗原蛋白，从而激发强效免疫反应。与传统疫苗相比，mRNA疫苗在研发效率、免疫效果及生物安全风险防控等方面，具备明显优势。
智通财经APP讯，瑞普生物(300119.SZ)发布公告，近日，公司收到了农业农村部颁发的猪流行性腹泻病毒mRNA疫苗(RPS1903)临床试验批件(批件号：2025061)。
此次获得的临床批件，是国内首个经济动物用mRNA疫苗临床批件。mRNA疫苗通过精准编码猪流行性腹泻病毒的关键抗原序列，进入机体后直接引导细胞合成抗原蛋白，从而激发强效免疫反应。与传统疫苗相比，mRNA疫苗在研发效率、免疫效果及生物安全风险防控等方面，具备明显优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.